Andreu Bofill Pumarola

Andreu Bofill Pumarola

Auto-generated profile, based on publicly available information

Andreu Bofill Pumarola

Barcelona Institute for Global Health, Hospital Clinic-University of Barcelona, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 January 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
KOKwabena Owusukyei
Kwabena Owusukyei
MBMaria Cussó Bordes
Maria Cussó Bordes
AFAugustin Eric Fombah
Augustin Eric Fombah
LQLlorenç Quintó
Llorenç Quintó
APAndreu Bofill Pumarola
Andreu Bofill Pumarola
CMClara Menéndez
Clara Menéndez
Background: Accurate data on morbidity and mortality among children under two years remain scarce in many low- and middle-income countries. We examined the causes and risk factors for severe morbidity and mortality among young children in Sierra Leone.Methods: We conducted a prospective cohort study nested within the ICARIA trial (NCT04235816), enrolling 20,560 infants aged 6–10 weeks between March 2021 and April 2024. The objective was to assess causes of hospital admission and death through 31 December 2024, when ~80% of children had completed 18-month follow-up. Hospital admissions, deaths, and immunisation status were captured through facility surveillance, household visits, phone follow-ups, and community informants. Causes of death were classified using ICD-10 and the WHO 2016 verbal autopsy tool (InSilicoVA). Incidence rates were expressed per 1,000 child-months. Morbidity was analysed using negative binomial regression; in-hospital and post-discharge mortality using Cox models and penalized logistic regression, reporting incidence rate ratios (IRRs), hazard ratios (HRs), and odds ratios (ORs).Findings: Median follow-up was 16·6 months. There were 2 688 hospital admissions (excluding readmissions and in-hospital deaths), yielding an incidence of 8·67 per 1 000 child-months. Malaria (54·3%), lower respiratory infections including pneumonia (16·7%), diarrhoeal disease (9·6%), undernutrition (7·4%), and sepsis (4·8%) were the leading causes of admission. Among in-hospital deaths (n=241), the leading causes were malaria (50·6%), lower respiratory infections (17·0%), sepsis (13·7%), undernutrition (7·1%), and diarrhoeal disease (3·7%). Among community deaths (n=425), malaria (24·2%), lower respiratory infections (17·9%), other infectious diseases (17·2%), and diarrhoeal disease (12·7%) predominated. Post-discharge mortality was 33·8 per 1 000 child-months. Undernutrition increased in-hospital mortality (adjusted OR 1·60, 95% CI 1·21–2·12). Full immunisation reduced overall (HR 0·65, 95% CI 0·55–0·76), in-hospital (OR 0·71, 95% CI 0·54–0·95), and post-discharge mortality (HR 0·56, 95% CI 0·33–0·92).Interpretation: This study shows that despite major investments and implementation efforts, mortality among infants and young children in Sierra Leone remains high and predominantly caused by preventable infections. These findings highlight the significant unfinished agenda in global health and the urgent need for more effective tools and strategies.

23 September 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
KOKwabena Owusukyei
Kwabena Owusukyei
LQLlorenç Quintó
Llorenç Quintó
AFAugustin Eric Fombah
Augustin Eric Fombah
JWJulian Williams
Julian Williams
MCMaureen N. Chileshe
Maureen N. Chileshe
CMClara Menéndez
Clara Menéndez
Background: Mass azithromycin administration for infants is recommended in high mortality settings. There is a need to assess the impact of integrating age-based azithromycin with other child survival strategies delivered through the Expanded Program on Immunisation (EPI).Methods: In this individually randomized, placebo-controlled trial in Sierra Leone, 20 560 infants were randomized to receive either azithromycin (20 mg/kg) or placebo during routine immunization visits at 6 weeks, 9 and 15 months of age. All participants received up to six doses of Perennial Malaria Chemoprevention (PMC) during immunization contacts. The primary outcome was all-cause mortality up to 18 months of age.Findings: There were 425 deaths in the azithromycin group and 463 in the placebo group (adjusted hazard ratio, 0·93; 95% confidence interval [CI], 0·82-1·06; p=0·30). Azithromycin was associated with lower mortality within 30 days after the first dose (adjusted hazard ratio, 0·49; 95% CI, 0·26 – 0·91; p=0·02), with similar size but non-significant effects after subsequent doses. Azithromycin was associated with an 18% lower hazard of mortality up to 18 months of age among children who died at home (60% of all deaths) (subdistribution hazard ratio, 0·82; 95% CI, 0·69 – 0·97; p=0·02). Over 70% of children received all three azithromycin or placebo doses. Adverse events were similar in the two groups. Receiving all PMC doses corresponding to age was independently associated with a 37% reduction in mortality (p<0·0001).Interpretation: Three doses of azithromycin administered over the first 15 months of life did not significantly reduce all-cause mortality at 18 months. However, the reduction in early mortality supports that alternative azithromycin schedules in early infancy warrant further evaluation. The survival benefits associated with PMC, together with high intervention coverage through EPI delivery, highlight the potential of integrated platforms to deliver multiple child-survival interventions at scale in high-mortality settings.

10 August 2026 in The Lancet Global Health
Verified
Journal Article
Open access
KOKwabena Owusu-Kyei
Kwabena Owusu-Kyei
MCMaria Cussó
Maria Cussó
AFAugustin Eric Fombah
Augustin Eric Fombah
LQLlorenç Quintó
Llorenç Quintó
ABAndreu Bofill
Andreu Bofill
VFVictoria Fumadó
Victoria Fumadó
Accurate data on morbidity and mortality in children younger than 2 years remain scarce in many low-income and middle-income countries. We aimed to examine the causes and risk factors for severe morbidity and mortality in young children in Sierra Leone. We conducted a prospective cohort study nested within a randomised controlled trial (NCT04235816). The study was done in 14 primary health facilities in three districts in Sierra Leone. We enrolled infants aged 6-10 weeks, eligible for pentavalent vaccine dose 1 through the EPI programme, weighing at least 2·5 kg, resident in the study area, without known contraindications to macrolides or sulfadoxine-pyrimethamine, between March 17, 2021, and April 25, 2024. The objective was to assess causes of hospital admission and death through to Dec 31, 2024, when approximately 80% of children had completed 18-month follow-up. Hospital admissions, deaths, and immunisation status were captured through facility surveillance, household visits, telephone follow-ups, and community informants. Causes of death were classified using ICD-10 and the WHO 2016 verbal autopsy tool (InSilicoVA). Incidence rates were expressed per 1000 child-months at risk. Morbidity was analysed using negative binomial regression; in-hospital mortality was analysed using penalised logistic regression, and post-discharge mortality was analysed using Cox proportional hazards regression. Data on severe morbidity and mortality were collected from 20 560 children, of whom 10 644 (52%) were male and 9916 (48%) were female; the most common ethnicity was Temne (14 048 [68%] of 20 551 children with available data). Median follow-up was 16·6 months (IQR 16·0-16·7). There were 2688 hospital admissions (excluding readmissions and in-hospital deaths), yielding an incidence of 8·67 per 1000 child-months at risk (95% CI 8·35-9·00). Malaria (1459 [54·3%] of 2688 admissions), lower respiratory tract infections including pneumonia (449 [16·7%]), diarrhoea (259 [9·6%]), undernutrition (198 [7·4%]), and sepsis (128 [4·8%]) were the leading causes of admission. The leading causes of in-hospital deaths were malaria (122 [50·6%] of 241), lower respiratory tract infections (41 [17·0%]), sepsis (33 [13·7%]), undernutrition (17 [7·1%]), and diarrhoea (nine [3·7%]). The leading causes of community deaths for which a verbal autopsy was performed were malaria (103 [24·2%] of 425), lower respiratory tract infections (76 [17·9%]), other infectious diseases (73 [17·2%]), and diarrhoea (54 [12·7%]). Post-discharge mortality was 33·8 per 1000 child-months at risk (95% CI 27·08-42·20). Being underweight was associated with higher in-hospital mortality compared with not being underweight (adjusted odds ratio [OR] 1·60 [95% CI 1·21-2·12]). Full immunisation was associated with lower overall mortality (adjusted hazard ratio [HR] 0·65 [95% CI 0·55-0·76]), lower in-hospital mortality (adjusted OR 0·71 [95% CI 0·54-0·95]), and lower post-discharge mortality (adjusted HR 0·56 [95% CI 0·33-0·92]). This study shows that despite major investments and implementation efforts, mortality in infants and young children in Sierra Leone remains high and predominantly caused by preventable infections. These findings highlight the substantial unfinished agenda in global health and the urgent need for more effective tools and strategies. Gates Foundation and La Caixa Foundation.